Comparison of the efficacy of zolmitriptan and sumatriptan: Issues in migraine trial design

Cephalalgia

Volumn 20, Issue 1, 2000, Pages 30-38

  Geraud, G ^a   Olesen, J ^b   Pfaffenrath, V ^c   Tfelt Hansen, P ^d   Zupping, R ^e   Diener, H C ^f   Sweet, R ^g  

^a CHU RANGUEIL   (France)

^b KAS Glostrup ^*  (Denmark)

^c Neurologe Münchener Freiheit   (Germany)

^d BISPEBJERG HOSPITAL   (Denmark)

^e Mustamae Hospital   (Estonia)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Migraine; Sumatriptan; Zolmitriptan

Indexed keywords

PLACEBO; SUMATRIPTAN; ZOLMITRIPTAN;

ADULT; AGED; ANALGESIA; ARTICLE; ASTHENIA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEAT SENSATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; NECK PAIN; PARESTHESIA; PHOTOPHOBIA; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; THORAX PAIN; TREATMENT OUTCOME; VERTIGO; VOMITING;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLES; OXAZOLIDINONES; RECURRENCE; RESEARCH DESIGN; SEROTONIN AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME; TRYPTAMINES;

EID: 0034464804     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2000.00004.x     Document Type: Article

References (20)

1. Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors
2. Migraine prevalence. A review of population-based studies
3. Epidemiology of headache
4. Prevalence and sex-ratio of the sub-types of migraine
5. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache
6. 1B/1D agonist for migraine
7. 1B/D agonist zolmitriptan (311C90): Are brain stem sites therapeutic targets in migraine?
8. Direct evidence for central sites of action of zolmitriptan (311C90): An autoradiographic study in cat
9. 1B/1D agonist zolmitriptan
10. Guidelines for controlled trials of drugs in migraine. 1st edn
11. Methodology of clinical trials of sumatriptan in migraine and cluster headache
12. How to define the best efficacy parameters for migraine
13. Verbal scales in the acute treatment of migraine: Semantic categories and clinical relevance
14. 1B/1D receptor agonists
15. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain
16. 1B/1D receptor agonist for the acute oral treatment of migraine: A multicentre, dose-range finding study
17. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study
18. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine
19. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90
20. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption